Eli Lilly Aims for $100 Billion Revenue Milestone with Strong Growth Projections
Eli Lilly is setting its sights on a significant revenue milestone of $100 billion by fiscal 2026, with management guiding for revenues between $85 billion and $87 billion. This ambitious target is underpinned by the company's strong performance in the incretin market, particularly through its products Mounjaro and Zepbound. Currently trading at $1,255.40, Eli Lilly has a price target of $1,480, indicating a potential upside of nearly 18% over the next year.
In recent weeks, Eli Lilly's stock has seen notable gains, rising 6.38% over the past week and 77.98% over the past year, as it approaches its 52-week high of $1,292.65. The company's second-quarter results for 2026 showcased a revenue of $22.97 billion, marking a year-over-year growth of 47.67%, which exceeded analyst expectations.
For Your Trading Desk
Sponsor Spike Success.
The growth trajectory is largely driven by the incretin franchise, which generated nearly $14.87 billion in a single quarter, with Mounjaro's international sales surging by 172%. Additionally, the anticipated global rollout of orforglipron in 2027 and the upcoming BLA for retatrutide in Q1 2027 are expected to further bolster revenue streams.
CEO David Ricks expressed optimism about the company's future, stating that it has never been brighter in its 150-year history. Analysts maintain a positive outlook, with a consensus of five strong-buy and 17 buy ratings, projecting a bull-case scenario price of $1,704.19, which reflects a total return of approximately 35.75%.
However, risks remain, particularly concerning revenue concentration, as Mounjaro and Zepbound account for over half of Eli Lilly's revenue. The competitive landscape is also evolving, with Novo Nordisk's Wegovy entering the oral GLP-1 market, which could impact Eli Lilly's market share.
Despite these challenges, Eli Lilly's forward P/E ratio of 35 is considered defensible given its growth prospects. The company continues to invest heavily in its pipeline, which includes promising candidates like Verve and Ataibeckley, while also managing the implications of recent IPR&D charges.
Overall, Eli Lilly's strategic positioning and robust product pipeline suggest a strong potential for achieving its ambitious revenue goals, making it a focal point for investors in the tech stock sector.




